Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

When journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck is attracting bullish attention due to its low valuation and strong dividend, but dark clouds hover over its future.